Group One Trading
IMUC

Group One Trading’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Group One Trading’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-125
Closed -$4K – 5875
2014
Q3 		$4K Sell
125
-605
-83% -$23.3K ﹤0.01% 4835
2014
Q2 		$33K Sell
730
-840
-54% -$40.5K ﹤0.01% 3839
2014
Q1 		$77K Sell
1,570
-3,703
-70% -$181K ﹤0.01% 3297
2013
Q4 		$195K Buy
5,273
+1,088
+26% +$103K ﹤0.01% 2457
2013
Q3 		$430K Buy
4,185
+972
+30% +$107K 0.01% 1750
2013
Q2 		$249K Buy
+3,213
New +$308K 0.01% 1961

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Group One Trading's IMUC Position: Q4 2016 in Review

Group One Trading sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 18 shares.

Group One Trading first reported a position in IMUC in Q2 2013 and held it in 11 quarters. The position peaked at $398K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Group One Trading reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Group One Trading sold 18 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016.
  • Group One Trading first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 11 quarters.
  • Group One Trading's ImmunoCellular Therapeutics, Ltd. position peaked at $398K in Q3 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Group One Trading's 13F filing for Q4 2016, filed 15 Feb 2017.